Test longer dosing of omalizumab for chronic hives
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This Phase 4 study looks at whether extending the time between omalizumab injections can still control chronic spontaneous hives (CSU). It may help some people need fewer injections while keeping symptoms under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have chronic spontaneous urticaria (CSU), confirmed by guideline-based diagnosis
- You have never taken omalizumab before starting this study
- You take four antihistamine tablets (or equivalents) every day for hives
- A clinician says you’re eligible for omalizumab based on local (Danish) guidelines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This study tests a new medication called HRS-3095 to see if it can help people whose chronic hives (itchy welts) do not get better with standard allergy pills. It aims to reduce itching and wheals and improve quality of life.
This trial tests whether adding apremilast, a medicine that reduces inflammation, helps people with chronic hives when antihistamines alone aren't enough. It may offer a new option for those who can't use other standard treatments like omalizumab or cyclosporine.
This study looks at people with severe hives (chronic urticaria) that have not improved with the usual dose of the medicine omalizumab. It aims to better understand these cases and how they are managed, which may help improve future care.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.